Relapsed Acute Myeloid Leukemia With Early Presentation As Leukemia Cutis, Refractory to Second-Line Treatment

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064173%3A_____%2F25%3A43928332" target="_blank" >RIV/00064173:_____/25:43928332 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11120/25:43928332

Výsledek na webu

<a href="https://doi.org/10.7759/cureus.80114" target="_blank" >https://doi.org/10.7759/cureus.80114</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.7759/cureus.80114" target="_blank" >10.7759/cureus.80114</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Relapsed Acute Myeloid Leukemia With Early Presentation As Leukemia Cutis, Refractory to Second-Line Treatment

Popis výsledku v původním jazyce

Acute myeloid leukemia (AML) is a hematologic malignancy with a poor prognosis, often presenting with systemic and extramedullary manifestations. Leukemia cutis (LC), the infiltration of leukemic cells into the skin, is a rare and clinically significant complication of AML. It often signals extramedullary disease involvement, may precede systemic relapse, and is associated with poor survival outcomes. We report the case of a 36-year-old female with AML who developed recurrent, reddish-brown nodular skin lesions on the face, trunk, and extremities, consistent with LC. Despite achieving initial remission with induction and consolidation chemotherapy, she experienced early LC recurrence, pancytopenia, hepatobiliary dysfunction, and infectious complications, underscoring the aggressive nature of her disease progression. Disease progression was confirmed by bone marrow evaluation, which revealed 60% blasts. Despite intensive chemotherapy, antimicrobial prophylaxis, and granulocyte colony-stimulating factor support, the patient&apos;s condition deteriorated due to refractory disease. This case suggests that LC may serve as a possible early marker of AML relapse, underscoring the importance of timely recognition and intervention. Multidisciplinary management and early diagnostic reassessment are essential to improving outcomes in such patients. Further research is needed to explore novel treatment strategies for AML patients with LC, aiming to enhance survival and disease control.

Název v anglickém jazyce

Relapsed Acute Myeloid Leukemia With Early Presentation As Leukemia Cutis, Refractory to Second-Line Treatment

Popis výsledku anglicky

Acute myeloid leukemia (AML) is a hematologic malignancy with a poor prognosis, often presenting with systemic and extramedullary manifestations. Leukemia cutis (LC), the infiltration of leukemic cells into the skin, is a rare and clinically significant complication of AML. It often signals extramedullary disease involvement, may precede systemic relapse, and is associated with poor survival outcomes. We report the case of a 36-year-old female with AML who developed recurrent, reddish-brown nodular skin lesions on the face, trunk, and extremities, consistent with LC. Despite achieving initial remission with induction and consolidation chemotherapy, she experienced early LC recurrence, pancytopenia, hepatobiliary dysfunction, and infectious complications, underscoring the aggressive nature of her disease progression. Disease progression was confirmed by bone marrow evaluation, which revealed 60% blasts. Despite intensive chemotherapy, antimicrobial prophylaxis, and granulocyte colony-stimulating factor support, the patient&apos;s condition deteriorated due to refractory disease. This case suggests that LC may serve as a possible early marker of AML relapse, underscoring the importance of timely recognition and intervention. Multidisciplinary management and early diagnostic reassessment are essential to improving outcomes in such patients. Further research is needed to explore novel treatment strategies for AML patients with LC, aiming to enhance survival and disease control.

Druh

J_ost - Ostatní články v recenzovaných periodicích

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Cureus

ISSN

2168-8184

e-ISSN

2168-8184

Svazek periodika

17

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

7

Strana od-do

"e80114"

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—